EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Discovery of Macrocyclic Peptide Inhibitors Targeting MYC Oncoprotein via mRNA Display

Jinzhu Chen iD, Fanglin Li, Chenguang Yuan iD, Xiaoling Geng, Yu Zhang, Qiurong Ding iD, Yan Chen iD

Pharmaceuticals · 22.06.2026 · 19 (6) · 967

DOI: 10.3390/ph19060967 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 22.06.2026. Verfasst von Jinzhu Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Hangzhou Institute for Advanced Study, Research Funds of Hangzhou Institute for Advanced Study, UCAS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: mRNA display technology has emerged as a powerful platform for discovering macrocyclic peptides against intractable proteins. However, direct screening against the “undruggable” transcription factor MYC using this approach remains largely unexplored. In this study, we aimed to integrate tyrosinase-mediated cyclization with mRNA display to identify novel macrocyclic peptide inhibitors targeting MYC.

Methods

We performed mRNA display combined with tyrosinase-mediated cyclization to generate macrocyclic peptides targeting MYC. Antiproliferative activity was assessed in MYC-dependent tumor cells using CCK8 assay. C-terminal fusions with a TAT-derived cell-penetrating peptide were generated to enhance cell membrane permeability. Binding affinities were measured by bio-layer interferometry (BLI). MYC transcriptional activity was evaluated by RNA sequencing (RNA-seq) analysis of canonical MYC target genes.

Results

The identified macrocyclic peptides exhibited potent antiproliferative activity against MYC-dependent tumor cells, with half-maximal inhibitory concentration (IC50) values in the micromolar range. Fusion with the TAT peptide improved antiproliferative potency, yielding IC50 values of 1–3 μM in MYC-dependent cell lines. BLI assays confirmed dose-dependent binding of the peptides to MYC, with dissociation constants (Kd) in the micromolar range. Furthermore, RNA-seq analysis revealed significant downregulation of canonical MYC target genes upon treatment with the TAT-fusion macrocyclic peptide, indicating specific suppression of MYC transcriptional activity.

Conclusions

This work establishes the feasibility of using mRNA display to target the “undruggable” protein MYC and identifies a panel of macrocyclic peptides as promising lead candidates for further optimization toward targeted therapies for MYC-driven cancers.

Schlagwörter

Stichwörter der Autor:innen

MYCmRNA displaymacrocyclic peptidetumor treatmentundruggable target

Autor:innen und Institutionen

  • Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China.
  • Shenzhen Sungening Biological Co., Ltd., Shenzhen 518172, China.
  • School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China.

ORCID-Profile: Jinzhu Chen, Chenguang Yuan, Qiurong Ding, Yan Chen

Förderung

  • National Natural Science Foundation of China
  • Hangzhou Institute for Advanced Study
  • Research Funds of Hangzhou Institute for Advanced Study, UCAS

Zitieren

APA

Chen, J., Li, F., Yuan, C., Geng, X., Zhang, Y., Ding, Q., & Chen, Y. (2026). Discovery of Macrocyclic Peptide Inhibitors Targeting MYC Oncoprotein via mRNA Display. Pharmaceuticals, 19(6), 967. https://doi.org/10.3390/ph19060967

Vancouver

Chen J, Li F, Yuan C, Geng X, Zhang Y, Ding Q, et al. Discovery of Macrocyclic Peptide Inhibitors Targeting MYC Oncoprotein via mRNA Display. Pharmaceuticals. 2026;19(6):967. doi:10.3390/ph19060967

BibTeX
@article{Chen2026,
  author = {Chen, Jinzhu and Li, Fanglin and Yuan, Chenguang and Geng, Xiaoling and Zhang, Yu and Ding, Qiurong and Chen, Yan},
  title = {Discovery of Macrocyclic Peptide Inhibitors Targeting MYC Oncoprotein via mRNA Display},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {6},
  pages = {967},
  doi = {10.3390/ph19060967}
}
Kostenlos starten →